<DOC>
	<DOCNO>NCT01762410</DOCNO>
	<brief_summary>Clinical study oral PI3K/mTOR inhibitor P7170 patient advance refractory solid tumor . The primary objective determine maximum tolerate dose dose limit toxicity oral PI3K/mTOR inhibitor P7170 patient advance refractory solid tumor</brief_summary>
	<brief_title>Clinical Study Oral PI3K/mTOR Inhibitor Patients With Advanced Refractory Solid Tumors</brief_title>
	<detailed_description>An open label multicentric Phase 1 study oral PI3K/mTOR inhibitor P7170 patient advance refractory solid tumors.The study follow Accelerated Titration Design ( ATD ) 100 % dose increment significant toxicity describe ; follow standard dose titration 40 % dose increment . Dose schedule ( alternate dose regimen eg . OD , BID , intermittent ) determine dose escalation outline protocol consider pharmacokinetics study drug determine early cohort .</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients histologically and/or cytologically confirm nonhaematological malignancy metastatic unresectable standard curative/palliative treatment exist longer effective tolerated patient . Patients either sex , race ethnic group , 18 year age . ECOG ( Eastern Cooperative Oncology Group ) performance status less 2 . Patients life expectancy least 4 month . Patients measurable evaluable disease per Response Evaluation Criteria In Solid Tumors ( RECIST ) version 1.1 . Patients must adequate organ marrow function define : Absolute neutrophil count equal 1500/cmm Platelets equal 100,000/cmm Total bilirubin within normal limit institution . AST/ALT le equal 2.5 X institutional upper limit normal ( ULN ) less equal 5 X institutional upper limit normal ( ULN ) presence liver metastases Creatinine le equal 1.5 X institutional upper limit normal ( ULN ) Women childbearing potential men willing agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation least 4 week withdrawal study , unless surgically sterilise . Ability understand willingness provide write informed consent document . 1 . Patients receive prior chemotherapy , radiotherapy , biologic/targeted anticancer therapy surgery within 4 week ( 3 month monoclonal antibody , radioactive monoclonal antibody radio toxin immunoconjugates ) study drug administration recover ( &lt; Grade 1 ) toxic effect prior therapy . 2 . Patients receive investigational agent within 4 week prior date enrolment recover completely ( &lt; Grade 1 ) side effect earlier investigational agent . 3 . Patients know brain metastasis ( except patient previouslytreated CNS metastasis , asymptomatic , requirement steroid antiseizure medication two month prior first dose study drug . ) 4 . Patients history myocardial infarction uncontrolled cardiac dysfunction previous 6 month . 5 . Patients diabetes mellitus require insulin therapy screen patient clinically significant diabetic complication , neuropathy , retinopathy , peripheral vascular disease nephropathy . 6 . Clinically significant medical condition malabsorption , inflammatory bowel disease , chronic diarrheal condition might affect absorption investigational agent . 7 . Patients chronic anticoagulation treatment . Prophylactic anticoagulation lowmolecular heparin allow . 8 . Patients intercurrent illness include , limited ongoing clinically significant active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 9 . Patients known history allergic reaction medication consider clinically significant investigator . 10 . Women pregnant nursing . 11 . Patients immune deficiency increase risk lethal infection , example , know h/o HIV , HBV HCV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Advanced refractory solid tumor</keyword>
</DOC>